--- title: Policy In Action description: RDDC advocates for historically marginalized populations to improve the standard of care & empower patient voices in all aspects of the healthcare process. image: https://www.rarediseasediversity.org/hubfs/Group%2030.png --- [Skip to main content](https://www.rarediseasediversity.org/policy-in-action#main) [![RDDC logo TM](https://www.rarediseasediversity.org/hubfs/RDDC-logo-TM.svg) ![RDDC logo TM Sticky](https://www.rarediseasediversity.org/hubfs/RDDC-logo-TM.svg) ![RDDC logo TM mobile](https://www.rarediseasediversity.org/hubfs/RDDC-logo-TM.svg) ![RDDC logo TM mobile sticky](https://www.rarediseasediversity.org/hubfs/RDDC-logo-TM.svg) ](https://www.rarediseasediversity.org?hsLang=en) - [Show submenu for About the Coalition About the Coalition ](https://www.rarediseasediversity.org/about) - [Our Team](https://www.rarediseasediversity.org/rddc-team) - [Advisory Council](https://www.rarediseasediversity.org/rddc-advisory-council) - [Industry Alliance](https://www.rarediseasediversity.org/industry-alliance) - [Partners](https://www.rarediseasediversity.org/rddc-partners) - [Show submenu for What We Do What We Do ](https://www.rarediseasediversity.org/what-we-do) - [Working Groups](https://www.rarediseasediversity.org/what-we-do) - [Policy In Action](https://www.rarediseasediversity.org/policy-in-action) - [Get Involved](https://www.rarediseasediversity.org/rddc-get-involved) - [Show submenu for Patient Support Patient Support ](https://www.rarediseasediversity.org/additional-patient-support) - [Breaking Barriers: Genetic Testing](https://www.rarediseasediversity.org/breaking-barriers) - [Patient Stories](https://www.rarediseasediversity.org/rddc-patient-stories) - [Show submenu for The Latest The Latest ](https://www.rarediseasediversity.org/the-latest) - [Opportunities](https://www.rarediseasediversity.org/rddc-opportunities) - [News & Announcements](https://www.rarediseasediversity.org/blog) - [Resources & Research](https://www.rarediseasediversity.org/research-resources) - [Events](https://www.rarediseasediversity.org/rddc-events) Open main navigation Close main navigation - Show submenu for About the Coalition About the Coalition - About the Coalition - [About the Coalition](https://www.rarediseasediversity.org/about) - [Our Team](https://www.rarediseasediversity.org/rddc-team) - [Advisory Council](https://www.rarediseasediversity.org/rddc-advisory-council) - [Industry Alliance](https://www.rarediseasediversity.org/industry-alliance) - [Partners](https://www.rarediseasediversity.org/rddc-partners) - Show submenu for What We Do What We Do - What We Do - [What We Do](https://www.rarediseasediversity.org/what-we-do) - [Working Groups](https://www.rarediseasediversity.org/what-we-do) - [Policy In Action](https://www.rarediseasediversity.org/policy-in-action) - [Get Involved](https://www.rarediseasediversity.org/rddc-get-involved) - Show submenu for Patient Support Patient Support - Patient Support - [Patient Support](https://www.rarediseasediversity.org/additional-patient-support) - [Breaking Barriers: Genetic Testing](https://www.rarediseasediversity.org/breaking-barriers) - [Patient Stories](https://www.rarediseasediversity.org/rddc-patient-stories) - Show submenu for The Latest The Latest - The Latest - [The Latest](https://www.rarediseasediversity.org/the-latest) - [Opportunities](https://www.rarediseasediversity.org/rddc-opportunities) - [News & Announcements](https://www.rarediseasediversity.org/blog) - [Resources & Research](https://www.rarediseasediversity.org/research-resources) - [Events](https://www.rarediseasediversity.org/rddc-events) - Search - [Donate](https://www.rarediseasediversity.org/?campaign=677445) [Donate](https://www.rarediseasediversity.org/?campaign=677445&hsLang=en) Search # RDDC Policy In Action RDDC advocates for legislation and policies that alleviate the disproportionate burden of rare diseases on historically marginalized populations, improve the standard of care, and empower patient voices in all aspects of the healthcare process. ![Policy Priorities Banner Image](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Group%2030.png?width=519&height=431&name=Group%2030.png) RDDC’s members and partner organizations are made up of rare disease experts, patients, health care professionals, diversity advocates, and industry leaders who advocate, guide, and provide current knowledge to help RDDC inform the Federal legislative and Administrative process. RDDC maintains extensive relationships with members of Congress and the Administrative branch, and furthers our important goals through a wide-range of actions, from directly speaking to policymakers, to introducing legislation and commenting on Administrative actions. ![RDDC 2026 Policy Priorities Image with a Ribbon.](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/2026-Policy-Priorities.webp?width=1447&height=1080&name=2026-Policy-Priorities.webp) ## RDDC Policy Reports [##### 2025 RDDC Annual Policy Report ](https://www.rarediseasediversity.org/hubfs/2025-RDDC-Annual-Policy-Report-compressed.pdf?hsLang=en) [##### 2024 Legislative Actions and Wins ](https://docs.google.com/presentation/d/1YWW5c_a0AFxPGk7ddnUu0pWoQGFQqQC5/edit#slide=id.g2fbc3453a50_0_0) ### Monitor & Support ###### Polices that encourage the clinical trial enrollment of patients with rare diseases and the study of off-label drugs. - [H.R. 3521](https://www.congress.gov/bill/119th-congress/house-bill/3521/text)  - Clinical Trail Modernization Act - [H.R. 6094](https://www.congress.gov/bill/118th-congress/house-bill/6094/text?s=1&r=1&q=%7B%22search%22%3A%22protect+rare%22%7D)  - PROTECT Rare Act --- ###### Funding to advance the study and treatment of rare disease and its impact on diverse populations. - [H.R. 4714](https://www.congress.gov/bill/118th-congress/house-bill/4714?s=4&r=4&q=%7B%22search%22%3A%22%5C%22rare+disease%5C%22%22%7D)  - Pediatricians Accelerate Childhood Therapies Act ([S. 2345](https://www.congress.gov/bill/118th-congress/senate-bill/2345)) - [S. 2333](https://www.congress.gov/bill/118th-congress/senate-bill/2333/text?s=4&r=12&q=%7B%22search%22%3A%22%5C%22rare+disease%5C%22%22%7D)  - Pandemic and All-Hazards Preparedness and Response Act - [H.R. 1750](https://www.congress.gov/119/bills/hr1750/BILLS-119hr1750ih.pdf)  - Health Equity and Rare Disease (HEARD) Act of 2025 --- ###### Long-term telehealth solutions, which improve and equalize access to specialized medical providers for rare disease patients. - [H.R. 1843](https://www.congress.gov/bill/118th-congress/house-bill/1843?q=%7B%22search%22%3A%22%5C%22telehealth%5C%22%22%7D&s=5&r=1)  - Telehealth Expansion Act of 2023 ([S. 1001](https://www.congress.gov/bill/118th-congress/senate-bill/1001)) - [H.R. 3440](https://www.congress.gov/bill/118th-congress/house-bill/3440?q=%7B%22search%22%3A%22%5C%22telehealth%5C%22%22%7D&s=5&r=6)  - Protecting Rural Telehealth Access Act ([S. 1636](https://www.congress.gov/bill/118th-congress/senate-bill/1636)) --- ###### Improved access to newborn screening and genetic testing, which can lead to early detection. - [H.R. 5864](https://www.congress.gov/bill/118th-congress/house-bill/5864?q=%7B%22search%22%3A%22%5C%22genetic+screening%5C%22%22%7D&s=6&r=1)  - Expanded Genetic Screening Act - [H.R. 4731](https://www.congress.gov/bill/118th-congress/house-bill/4731/text?s=7&r=1&q=%7B%22search%22%3A%22%5C%22genetic+screening%5C%22%22%7D)  - Access to Infertility Treatment and Care Act ([S. 2386](https://www.congress.gov/bill/118th-congress/senate-bill/2386)) --- ###### Policies that support Medicare Dependent Hospitals (MDHs) that support rural communities. - [S. 1110](https://www.congress.gov/bill/118th-congress/senate-bill/1110/text?s=9&r=1)  - Rural Hospital Support Act - [H.R. 6430](https://www.congress.gov/bill/118th-congress/house-bill/6430/text?s=2&r=1)  - Assistance for Rural Community Hospitals Act (“ARCH”) --- ## Comment Letters [##### S. 4440, the Clinical Trial Modernization Act Support Letter ](https://www.rarediseasediversity.org/hubfs/RDDC/pdf/119th-SenateCTMA-Support-Letter.pdf?hsLang=en) [##### FDA Guidance for Industry: FDA-2025-D-1797 ](https://www.rarediseasediversity.org/hubfs/RDDC/pdf/Comment-Letter-on-Pregnant-and-Breastfeeding-Woman-and-Clinical-Trials-Final.pdf?hsLang=en) [##### NIH Artificial Intelligence Strategic Plan ](https://www.rarediseasediversity.org/hubfs/RDDC/pdf/RDDC-RFI-on-NIH-Artificial-Intelligence-Strategic-Plan.pdf?hsLang=en) [##### H.R. 3521, Clinical Trial Modernization Act ](https://www.rarediseasediversity.org/hubfs/RDDC/pdf/119th-CTMA-Support-Letter.pdf?hsLang=en) [##### H.R. 4758 Accelerating Kid’s Access to Care Act ](https://www.rarediseasediversity.org/hubfs/RDDC/pdf/RDDC-Letter-to-Advance-HR-4758-Accelerating-Kids%20Access-to-Care-Act-2.pdf?hsLang=en) [##### RDDC's Comments on the FDA Draft Guidance ](https://www.rarediseasediversity.org/hubfs/RDDC/pdf/Comments-on-FDA-Guidance-on-DAPS.pdf?hsLang=en) ## Our Diversity Action Plan Recommendations - ###### FDA Should Include the Development of Diversity Action Plans in the Roles and Responsibilities of Sponsors of DCTs - ###### FDA Should Recommend Clinical Trial Sponsors Engage Patient Experiences When Developing of Decentralized Clinical Trials - ###### FDA Should Recommend Clinical Trial Sponsors to Consider and Address Barriers that May Inhibit Patient Use of Digital Healthcare Technologies - ###### FDA Should Recommend Clinical Trial Sponsors to Partner with Community, Faith-Based, Nonprofit, and Patient Advocacy Organizations to Recruit Diverse Participants Diversity action plans are critical for clinical trial sponsors to consistently implement actions to improve racial and ethnic diversity in DCTs. Enrollment of a representative number of participants from underrepresented racial and ethnic populations helps ensure that the data generated in clinical trials and studies reflect the racial and ethnic diversity of the population expected to use drugs and medical products and may assist in identifying effects on safety or efficacy outcomes that may be associated with, or occur more frequently within these populations. While the FDA has published draft guidance for diversity action plans for the clinical trials generally, RDDC strongly recommends the FDA include the development of diversity action plans in the roles and responsibilities of DCT sponsors and develop specific guidance, or expand current guidance, for diversity action plans that account for the unique structure of DCTs. As discussed above, DCTs offer unique benefits for increasing participation in clinical trials. The remote or hybrid trial design and the unique and innovative technological solutions employed by DCTs may necessitate additional consideration when developing diversity action plans. Specifically, in the formulation of the diversity action plan clinical trial sponsors should consider how decentralized features of the trial may be employed to increase participant diversity, and analyze which decentralized features will best meet diversity enrollment goals. Further, the action plan should describe specific trial enrollment and retention strategies that may be specific DCTs, including: digital health technology proficiency, language assistance, access to broadband required for use of decentralized technologies, and modification of technologies for persons with disabilities. Patients may have more responsibilities in a DCT, and understanding their ability and willingness to meet these responsibilities is critical for the success and diversification of the trial. RDDC strongly urges FDA to include recommendations for clinical trial sponsors to engage patients and patient experiences when developing DCTs. Patient perspectives are essential in understanding the diseases or conditions at focus of the DCT, conceptualizing clinical benefits and risks, and ensuring the DCT is designed in a way that supports successful patient engagement. This is especially true for patients with rare diseases, who may face unique challenges accessing certain health technologies, in-person trial locations, and quality healthcare. Incorporating patient experiences in clinical trial design will assist the trial sponsor in understanding the clinical environment in which patients with the condition seek care, the patient and/or caregiver perspectives on the disease, its impacts, and therapeutic needs and priorities. By considering which aspect(s) of the patient experience are most effected by the disease or condition, clinical trial design, technology employed, and trial objectives and endpoints can be most effectively developed to ensure the most optimal applicability for patients and encourage full participation. We are aware that the FDA is in the current process of developing guidance for the incorporation of patients' voices in medical product development and regulatory decision making. However, developing guidance for enhancing and incorporating patient voices cannot be successful if it is not encouraged consistently throughout other FDA guidance, including the development of DCTs. A core aspect of DCTs is the deployment of digital health technologies (DHTs) that broaden the range of participation in the clinical trial and in the data. These technologies span a wide range of uses, from applications in general wellness to applications of medical devices. However, without addressing participant barriers in relation to the introduction of new technologies, DCTs cannot ensure participation from the lowest socioeconomic groups. Many patients from underserved populations, especially those with rare diseases, do not have access to broadband or lack the sufficient technology or training to use digital healthcare technologies. In addition to recommending clinical trial sponsors to ensure the availability of DHTs for all DCT participants, FDA should encourage sponsors to provide training and resources as necessary for participants who may lack the technological proficiency, broadband, or other technological infrastructure required for participation and establish specific protocol in the case of technological unavailability or failure. FDA should also encourage sponsors to analyze any additional technological barriers that may prevent certain socioeconomic groups and rural individuals from trial participation. Comprehensive recruitment strategies can enable clinical trial sponsors to recruit more diverse participants. While the Draft Guidance recommends some actions sponsors may take to partner with organizations, the FDA should expand the guidance to recommend sponsors partner with community, faith-based, nonprofit, and patient advocacy organizations for participant recruitment. These types of organizations often have membership groups and connections with local communities and are on the front line communicating within a diverse communities. These partnerships can sustain long-term DCT viability because these organizations can serve as hubs for clinical trial recruitment and other training that may be necessary for DCT participation.  In 2022 and 2023, RDDC partnered with Upequity to conduct an online survey titled *Diversity, Equity, and Inclusion Efforts in Rare Disease Organizations Survey* (DEI Survey). The DEI survey was developed to address rare disease patient organization's related to outreach, education, and support of patients of color with rare diseases. Based on the results of the survey, RDDC developed a set of recommendations to increase DEI across different organizations, including pursuing diversity in clinical trial recommendations. Specifically, the report recommends a series of actions clinical trial sponsors and other organizations can employ to increase the outreach to patients of color with rare diseases. The FDA should incorporate these recommendations into the Draft Guidance to ensure there are effective recruitment strategies. The recommendations include: - Post clinical trial information on patient advocacy organization’s websites, social media, and other public-facing communication methods. - Create a lay guide that provides an overview of what a clinical trial is and how to participate. - Provide opportunities for the public to participate in forums that serve as an educational tool for families, including those living with rare disease, to address clinical trial information. - Provide information about clinical trials through all modes of communication, even those outside of social media. - Engage in targeted recruitment efforts of underserved/minority populations. ###### FDA Should Include the Development of Diversity Action Plans in the Roles and Responsibilities of Sponsors of DCTs Diversity action plans are critical for clinical trial sponsors to consistently implement actions to improve racial and ethnic diversity in DCTs. Enrollment of a representative number of participants from underrepresented racial and ethnic populations helps ensure that the data generated in clinical trials and studies reflect the racial and ethnic diversity of the population expected to use drugs and medical products and may assist in identifying effects on safety or efficacy outcomes that may be associated with, or occur more frequently within these populations. While the FDA has published draft guidance for diversity action plans for the clinical trials generally, RDDC strongly recommends the FDA include the development of diversity action plans in the roles and responsibilities of DCT sponsors and develop specific guidance, or expand current guidance, for diversity action plans that account for the unique structure of DCTs. As discussed above, DCTs offer unique benefits for increasing participation in clinical trials. The remote or hybrid trial design and the unique and innovative technological solutions employed by DCTs may necessitate additional consideration when developing diversity action plans. Specifically, in the formulation of the diversity action plan clinical trial sponsors should consider how decentralized features of the trial may be employed to increase participant diversity, and analyze which decentralized features will best meet diversity enrollment goals. Further, the action plan should describe specific trial enrollment and retention strategies that may be specific DCTs, including: digital health technology proficiency, language assistance, access to broadband required for use of decentralized technologies, and modification of technologies for persons with disabilities. ###### FDA Should Recommend Clinical Trial Sponsors Engage Patient Experiences When Developing of Decentralized Clinical Trials Patients may have more responsibilities in a DCT, and understanding their ability and willingness to meet these responsibilities is critical for the success and diversification of the trial. RDDC strongly urges FDA to include recommendations for clinical trial sponsors to engage patients and patient experiences when developing DCTs. Patient perspectives are essential in understanding the diseases or conditions at focus of the DCT, conceptualizing clinical benefits and risks, and ensuring the DCT is designed in a way that supports successful patient engagement. This is especially true for patients with rare diseases, who may face unique challenges accessing certain health technologies, in-person trial locations, and quality healthcare. Incorporating patient experiences in clinical trial design will assist the trial sponsor in understanding the clinical environment in which patients with the condition seek care, the patient and/or caregiver perspectives on the disease, its impacts, and therapeutic needs and priorities. By considering which aspect(s) of the patient experience are most effected by the disease or condition, clinical trial design, technology employed, and trial objectives and endpoints can be most effectively developed to ensure the most optimal applicability for patients and encourage full participation. We are aware that the FDA is in the current process of developing guidance for the incorporation of patients' voices in medical product development and regulatory decision making. However, developing guidance for enhancing and incorporating patient voices cannot be successful if it is not encouraged consistently throughout other FDA guidance, including the development of DCTs. ###### FDA Should Recommend Clinical Trial Sponsors to Consider and Address Barriers that May Inhibit Patient Use of Digital Healthcare Technologies A core aspect of DCTs is the deployment of digital health technologies (DHTs) that broaden the range of participation in the clinical trial and in the data. These technologies span a wide range of uses, from applications in general wellness to applications of medical devices. However, without addressing participant barriers in relation to the introduction of new technologies, DCTs cannot ensure participation from the lowest socioeconomic groups. Many patients from underserved populations, especially those with rare diseases, do not have access to broadband or lack the sufficient technology or training to use digital healthcare technologies. In addition to recommending clinical trial sponsors to ensure the availability of DHTs for all DCT participants, FDA should encourage sponsors to provide training and resources as necessary for participants who may lack the technological proficiency, broadband, or other technological infrastructure required for participation and establish specific protocol in the case of technological unavailability or failure. FDA should also encourage sponsors to analyze any additional technological barriers that may prevent certain socioeconomic groups and rural individuals from trial participation. ###### FDA Should Recommend Clinical Trial Sponsors to Partner with Community, Faith-Based, Nonprofit, and Patient Advocacy Organizations to Recruit Diverse Participants Comprehensive recruitment strategies can enable clinical trial sponsors to recruit more diverse participants. While the Draft Guidance recommends some actions sponsors may take to partner with organizations, the FDA should expand the guidance to recommend sponsors partner with community, faith-based, nonprofit, and patient advocacy organizations for participant recruitment. These types of organizations often have membership groups and connections with local communities and are on the front line communicating within a diverse communities. These partnerships can sustain long-term DCT viability because these organizations can serve as hubs for clinical trial recruitment and other training that may be necessary for DCT participation.  In 2022 and 2023, RDDC partnered with Upequity to conduct an online survey titled *Diversity, Equity, and Inclusion Efforts in Rare Disease Organizations Survey* (DEI Survey). The DEI survey was developed to address rare disease patient organization's related to outreach, education, and support of patients of color with rare diseases. Based on the results of the survey, RDDC developed a set of recommendations to increase DEI across different organizations, including pursuing diversity in clinical trial recommendations. Specifically, the report recommends a series of actions clinical trial sponsors and other organizations can employ to increase the outreach to patients of color with rare diseases. The FDA should incorporate these recommendations into the Draft Guidance to ensure there are effective recruitment strategies. The recommendations include: - Post clinical trial information on patient advocacy organization’s websites, social media, and other public-facing communication methods. - Create a lay guide that provides an overview of what a clinical trial is and how to participate. - Provide opportunities for the public to participate in forums that serve as an educational tool for families, including those living with rare disease, to address clinical trial information. - Provide information about clinical trials through all modes of communication, even those outside of social media. - Engage in targeted recruitment efforts of underserved/minority populations. Monitor & Support - Polices that encourage the clinical trial enrollment of patients with rare diseases and the study of off-label drugs. - [H.R. 6094](https://www.congress.gov/bill/118th-congress/house-bill/6094/text?s=1&r=1&q=%7B%22search%22%3A%22protect+rare%22%7D)  - PROTECT Rare Act - Funding to advance the study and treatment of rare disease and its impact on diverse populations. - [H.R. 4714](https://www.congress.gov/bill/118th-congress/house-bill/4714?s=4&r=4&q=%7B%22search%22%3A%22%5C%22rare+disease%5C%22%22%7D) – Pediatricians Accelerate Childhood Therapies Act  ([S. 2345](https://www.congress.gov/bill/118th-congress/senate-bill/2345)) - [S. 2333](https://www.congress.gov/bill/118th-congress/senate-bill/2333/text?s=4&r=12&q=%7B%22search%22%3A%22%5C%22rare+disease%5C%22%22%7D) – Pandemic and All-Hazards Preparedness and Response Act - Long-term telehealth solutions, which improve and equalize access to specialized medical providers for rare disease patients. - [H.R. 1843](https://www.congress.gov/bill/118th-congress/house-bill/1843?q=%7B%22search%22%3A%22%5C%22telehealth%5C%22%22%7D&s=5&r=1) – Telehealth Expansion Act of 2023 ([S. 1001](https://www.congress.gov/bill/118th-congress/senate-bill/1001)) - [H.R. 3440](https://www.congress.gov/bill/118th-congress/house-bill/3440?q=%7B%22search%22%3A%22%5C%22telehealth%5C%22%22%7D&s=5&r=6) – Protecting Rural Telehealth Access Act  ([S. 1636](https://www.congress.gov/bill/118th-congress/senate-bill/1636)) - Improved access to newborn screening and genetic testing, which can lead to early detection. - [H.R. 5864](https://www.congress.gov/bill/118th-congress/house-bill/5864?q=%7B%22search%22%3A%22%5C%22genetic+screening%5C%22%22%7D&s=6&r=1) – Expanded Genetic Screening Act - [H.R. 4731](https://www.congress.gov/bill/118th-congress/house-bill/4731/text?s=7&r=1&q=%7B%22search%22%3A%22%5C%22genetic+screening%5C%22%22%7D) – Access to Infertility Treatment and Care Act ([S. 2386](https://www.congress.gov/bill/118th-congress/senate-bill/2386)) - Policies that support Medicare Dependent Hospitals (MDHs) that support rural communities.  - [S. 1110](https://www.congress.gov/bill/118th-congress/senate-bill/1110/text?s=9&r=1) – Rural Hospital Support Act - [H.R. 6430](https://www.congress.gov/bill/118th-congress/house-bill/6430/text?s=2&r=1) – Assistance for Rural Community Hospitals Act (“ARCH”) ## Our Partners [![The Aarskog Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/The-Aarskog-Foundation.png?width=150&height=80&name=The-Aarskog-Foundation.png) ](https://www.aarskogsyndromefoundation.co.uk) [![association-of-black-cardiologists](https://www.rarediseasediversity.org/hs-fs/hubfs/association-of-black-cardiologists.png?width=150&height=80&name=association-of-black-cardiologists.png) ](https://abcardio.org) [![abcuro logo: Click to visit their web site](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/abcuro.png?width=150&height=80&name=abcuro.png) ](https://abcuro.com) [![accessia health logo](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/accessia-health.png?width=150&height=80&name=accessia-health.png) ](https://accessiahealth.org) [![The Akari Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/The-Akari-Foundation.png?width=150&height=80&name=The-Akari-Foundation.png) ](https://theakarifoundation.org) [![ALS Association](https://www.rarediseasediversity.org/hs-fs/hubfs/ALS-Association.png?width=150&height=80&name=ALS-Association.png) ](https://www.als.org) [![Alliance for Black NICU Families](https://www.rarediseasediversity.org/hs-fs/hubfs/Alliance-for-Black-NICU-Families.png?width=150&height=80&name=Alliance-for-Black-NICU-Families.png) ](https://blacknicufamilies.org) [![amgen](https://www.rarediseasediversity.org/hs-fs/hubfs/amgen.png?width=150&height=80&name=amgen.png) ](https://www.amgen.com) [![American Kidney Fund](https://www.rarediseasediversity.org/hs-fs/hubfs/americankidney.png?width=150&height=80&name=americankidney.png) ](https://www.kidneyfund.org) [![American Muslim Health Professionals (AMHP)](https://www.rarediseasediversity.org/hs-fs/hubfs/American-Muslim-Health-Professionals-AMHP.png?width=150&height=80&name=American-Muslim-Health-Professionals-AMHP.png) ](https://amhp.us) [![Amicus](https://www.rarediseasediversity.org/hs-fs/hubfs/Amicus.png?width=150&height=80&name=Amicus.png) ](https://amicusrx.com) [![ArgenX](https://www.rarediseasediversity.org/hs-fs/hubfs/ArgenX.png?width=150&height=80&name=ArgenX.png) ](https://www.argenx.com) [![Association of American Indian Physicians](https://www.rarediseasediversity.org/hs-fs/hubfs/Association-of-American-Indian-Physicians.png?width=150&height=80&name=Association-of-American-Indian-Physicians.png) ](https://www.aaip.org) [![The Assistance Fund](https://www.rarediseasediversity.org/hs-fs/hubfs/The-Assistance-Fund.png?width=150&height=80&name=The-Assistance-Fund.png) ](https://tafcares.org) [![Sickle Cell Disease Association of America](https://www.rarediseasediversity.org/hs-fs/hubfs/Sickle-Cell%20Disease-Association-of-America.png?width=150&height=80&name=Sickle-Cell%20Disease-Association-of-America.png) ](https://www.sicklecelldisease.org) [![Astria Therapeutics](https://www.rarediseasediversity.org/hs-fs/hubfs/Astria-Therapeutics.png?width=150&height=80&name=Astria-Therapeutics.png) ](https://astriatx.com) [![The Balm in Gilead Inc. ](https://www.rarediseasediversity.org/hs-fs/hubfs/The-Balm-in-Gilead-Inc.png?width=150&height=80&name=The-Balm-in-Gilead-Inc.png) ](https://www.balmingilead.org) [![bridgebio](https://www.rarediseasediversity.org/hs-fs/hubfs/bridgebio.png?width=150&height=80&name=bridgebio.png) ](https://bridgebio.com) [![Boehringer Ingelheim](https://www.rarediseasediversity.org/hs-fs/hubfs/Boehringer-Ingelheim.png?width=150&height=80&name=Boehringer-Ingelheim.png) ](https://www.boehringer-ingelheim.com) [![CACNA1A Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/CACNA1A-Foundation.png?width=150&height=80&name=CACNA1A-Foundation.png) ](https://www.cacna1a.org) [![Caring Families](https://www.rarediseasediversity.org/hs-fs/hubfs/Caring-Families.png?width=150&height=80&name=Caring-Families.png) ](https://www.carefamilies.com) [![Childrens National Hospital](https://www.rarediseasediversity.org/hs-fs/hubfs/Childrens-National-Hospital-2.png?width=150&height=80&name=Childrens-National-Hospital-2.png) ](https://childrensnational.org) [![American College of CHEST Physicians](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Chest-American-College.png?width=150&height=80&name=Chest-American-College.png) ](https://www.chestnet.org) [![CombinedBrain](https://www.rarediseasediversity.org/hs-fs/hubfs/CombinedBrain.png?width=150&height=80&name=CombinedBrain.png) ](https://combinedbrain.org) [![Cincinnati Children's](https://www.rarediseasediversity.org/hs-fs/hubfs/Cincinnati-Childrens.png?width=150&height=80&name=Cincinnati-Childrens.png) ](https://www.cincinnatichildrens.org) [![Couch Pennies Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/Couch-Pennies-Foundation.png?width=150&height=80&name=Couch-Pennies-Foundation.png) ](https://www.facebook.com/couchpenniesfoundation) [![National CMV Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/National-CMV-Foundation.png?width=150&height=80&name=National-CMV-Foundation.png) ](https://www.nationalcmv.org) [![Elevate-Advocacy](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Elevate-Advocacy.png?width=150&height=80&name=Elevate-Advocacy.png) ](https://www.elevateadvocacy.com) [![Entrada Therapeutics](https://www.rarediseasediversity.org/hs-fs/hubfs/Entrada-Therapeutics.png?width=150&height=80&name=Entrada-Therapeutics.png) ](https://www.entradatx.com) [![Epilepsy Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/Epilepsy-Foundation.png?width=150&height=80&name=Epilepsy-Foundation.png) ](https://www.epilepsy.com) [![Expecting Health](https://www.rarediseasediversity.org/hs-fs/hubfs/Expecting-Health.png?width=150&height=80&name=Expecting-Health.png) ](https://www.expectinghealth.org) [![EveryLife Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/EveryLife-Foundation.png?width=150&height=80&name=EveryLife-Foundation.png) ](https://everylifefoundation.org) [![E.WE Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/E-WE-Foundation.png?width=150&height=80&name=E-WE-Foundation.png) ](https://theewefoundation.org) [![FSHD Society](https://www.rarediseasediversity.org/hs-fs/hubfs/FSHD-Society.png?width=150&height=80&name=FSHD-Society.png) ](https://www.fshdsociety.org) [![Prader-Willi-Research](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Prader-Willi-Research.png?width=150&height=80&name=Prader-Willi-Research.png) ](https://www.fpwr.org/) [![Foundation for Sarcoidosis Research](https://www.rarediseasediversity.org/hs-fs/hubfs/Foundation-for-Sarcoidosis-Research.png?width=150&height=80&name=Foundation-for-Sarcoidosis-Research.png) ](https://www.stopsarcoidosis.org) [![GeneDx](https://www.rarediseasediversity.org/hubfs/RDDC/GeneDx.svg) ](https://www.genedx.com) [![GFPD (Global Foundation for Peroxisomal Disorders)](https://www.rarediseasediversity.org/hs-fs/hubfs/GFPD-Global-Foundation-for-Peroxisomal-Disorders.png?width=150&height=80&name=GFPD-Global-Foundation-for-Peroxisomal-Disorders.png) ](https://thegfpd.org) [![Gillette Childrens](https://www.rarediseasediversity.org/hs-fs/hubfs/Gillette-Childrens.png?width=150&height=80&name=Gillette-Childrens.png) ](https://www.gillettechildrens.org) [![Glaukos Corporation logo](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Glaukos-Corporation.png?width=150&height=80&name=Glaukos-Corporation.png) ](https://www.glaukos.com) [![Global Genes](https://www.rarediseasediversity.org/hs-fs/hubfs/Global-Genes.png?width=150&height=80&name=Global-Genes.png) ](https://globalgenes.org) [![Global Liver Institute](https://www.rarediseasediversity.org/hs-fs/hubfs/Global-Liver-Institute.png?width=150&height=80&name=Global-Liver-Institute.png) ](https://globalliver.org) [![Glo Preemies](https://www.rarediseasediversity.org/hs-fs/hubfs/Glo-Preemies.png?width=150&height=80&name=Glo-Preemies.png) ](https://www.glopreemies.org) [![Guthy-Jackson](https://www.rarediseasediversity.org/hs-fs/hubfs/Guthy-Jackson.png?width=150&height=80&name=Guthy-Jackson.png) ](https://guthyjacksonfoundation.org/) [![Click to view Harrmony Biosciences web site](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Harrmony-Biosciences.png?width=150&height=80&name=Harrmony-Biosciences.png) ](https://www.harmonybiosciences.com) [![Histiocytosis Association](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Histiocytosis-Association.png?width=150&height=80&name=Histiocytosis-Association.png) ](https://histio.org) [![Holland & Knight](https://www.rarediseasediversity.org/hs-fs/hubfs/hklaw.png?width=150&height=80&name=hklaw.png) ](https://www.hklaw.com/en) [![Immune Deficiency Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Immune-Deficiency-Foundation.png?width=150&height=80&name=Immune-Deficiency-Foundation.png) ](https://primaryimmune.org) [![indousrare](https://www.rarediseasediversity.org/hs-fs/hubfs/indousrare.png?width=150&height=80&name=indousrare.png) ](https://www.indousrare.org) [![Click to view ionis web site](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/ionis.png?width=150&height=80&name=ionis.png) ](https://ionis.com) [![The LAM Foudation](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/LAM-Foudation.webp?width=150&height=80&name=LAM-Foudation.webp) ](https://www.thelamfoundation.org) [![LGS Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/LGS-Foundation.png?width=150&height=80&name=LGS-Foundation.png) ](https://www.lgsfoundation.org) [![MANA A National Latina Organization](https://www.rarediseasediversity.org/hs-fs/hubfs/MANA-A-National-Latina-Organization.png?width=150&height=80&name=MANA-A-National-Latina-Organization.png) ](https://www.hermana.org) [![​Melanin Children Matter Logo](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/%E2%80%8BMelanin-Children-Matter.png?width=150&height=80&name=%E2%80%8BMelanin-Children-Matter.png) ](https://www.melaninchildrenmatter.org) [![Mission-Cure](https://www.rarediseasediversity.org/hs-fs/hubfs/Mission-Cure.png?width=150&height=80&name=Mission-Cure.png) ](https://mission-cure.org) [![Muscular Dystrophy Association](https://www.rarediseasediversity.org/hs-fs/hubfs/Muscular-Dystrophy-Association.png?width=150&height=80&name=Muscular-Dystrophy-Association.png) ](https://www.mda.org) [![Myasthenia Gravis Foundation of America, Inc](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Myasthenia-Gravis-Foundation.png?width=150&height=80&name=Myasthenia-Gravis-Foundation.png) ](https://myasthenia.org) [![nac (National Alliance for Caregiving)](https://www.rarediseasediversity.org/hs-fs/hubfs/nac-National-Alliance-for-Caregiving.png?width=150&height=80&name=nac-National-Alliance-for-Caregiving.png) ](https://www.caregiving.org) [![NBNA (National Black Nurses Association Inc.)](https://www.rarediseasediversity.org/hs-fs/hubfs/NBNA.png?width=150&height=80&name=NBNA.png) ](https://www.nbna.org) [![National Genetics Education and Family Support ](https://www.rarediseasediversity.org/hs-fs/hubfs/National-Genetics-Education-2.png?width=150&height=80&name=National-Genetics-Education-2.png) ](https://nationalfamilycenter.org) [![NHMA (National Hispanic Medical Association)](https://www.rarediseasediversity.org/hs-fs/hubfs/NHMA.png?width=150&height=80&name=NHMA.png) ](https://www.nhmamd.org) [![National-Bleeding-Disorders](https://www.rarediseasediversity.org/hs-fs/hubfs/National-Bleeding-Disorders.png?width=150&height=80&name=National-Bleeding-Disorders.png) ](https://www.hemophilia.org/who-we-are) [![National Institute of Health](https://www.rarediseasediversity.org/hs-fs/hubfs/National-Institure-of-Health.png?width=150&height=80&name=National-Institure-of-Health.png) ](https://www.nih.gov) [![NMA (National Medical Association)](https://www.rarediseasediversity.org/hs-fs/hubfs/NMA.png?width=150&height=80&name=NMA.png) ](https://www.nmanet.org) [![Nephcure Kidney International](https://www.rarediseasediversity.org/hs-fs/hubfs/Nephcure-Kidney-International.png?width=150&height=80&name=Nephcure-Kidney-International.png) ](https://nephcure.org) [![NORD (National Organization for Rare Disorders)](https://www.rarediseasediversity.org/hs-fs/hubfs/NORD.png?width=150&height=80&name=NORD.png) ](https://rarediseases.org) [![Novartis Logo](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Novartis.png?width=150&height=80&name=Novartis.png) ](https://www.novartis.com) [![PAN (Patient Access Network) Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/PAN.png?width=150&height=80&name=PAN.png) ](https://www.panfoundation.org) [![PAF (Patient Advocate Foundation)](https://www.rarediseasediversity.org/hs-fs/hubfs/PAF-Patient-Advocate-Foundation.png?width=150&height=80&name=PAF-Patient-Advocate-Foundation.png) ](https://www.patientadvocate.org) [![Patients Rising logo](https://www.rarediseasediversity.org/hs-fs/hubfs/Patients-Rising.png?width=150&height=80&name=Patients-Rising.png) ](https://www.patientsrising.org) [![pcori (Patient centered outcomes research institute)](https://www.rarediseasediversity.org/hs-fs/hubfs/pcori.png?width=150&height=80&name=pcori.png) ](https://www.pcori.org) [![Prevent Blindness](https://www.rarediseasediversity.org/hs-fs/hubfs/Prevent-Blindness.png?width=150&height=80&name=Prevent-Blindness.png) ](https://preventblindness.org) [![Rare Rising Logo](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/RareRising-2-logo-1.webp?width=150&height=80&name=RareRising-2-logo-1.webp) ](https://rarerising.org) [![SAPHA](https://www.rarediseasediversity.org/hs-fs/hubfs/SAPHA.png?width=150&height=80&name=SAPHA.png) ](https://www.sapha.org) [![Scleroderma Research Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/Scleroderma-Research-Foundation.png?width=150&height=80&name=Scleroderma-Research-Foundation.png) ](https://srfcure.org) [![Scleroderma United](https://www.rarediseasediversity.org/hs-fs/hubfs/Scleroderma-United.png?width=150&height=80&name=Scleroderma-United.png) ](https://www.sclerounited.us) [![SCARED (Sickle Cell Reproductive Health Education Directive)](https://www.rarediseasediversity.org/hs-fs/hubfs/SCRED.png?width=150&height=80&name=SCRED.png) ](https://sicklecellred.org) [![Sickle inspired](https://www.rarediseasediversity.org/hs-fs/hubfs/Sickle-inspired.png?width=150&height=80&name=Sickle-inspired.png) ](https://www.instagram.com/sickle.inspired/?hl=en) [![Sobi](https://www.rarediseasediversity.org/hs-fs/hubfs/Sobi.png?width=150&height=80&name=Sobi.png) ](https://www.sobi.com/en) [![Sociedad Hispana de Enfermedades Raras](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Sociedad-Hispana-de-Enfermedades-Raras.png?width=150&height=80&name=Sociedad-Hispana-de-Enfermedades-Raras.png) ](https://www.hispanicsocietyrarediseases.org) [![Sumaira-Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/Sumaira-Foundation.png?width=150&height=80&name=Sumaira-Foundation.png) ](https://www.sumairafoundation.org) [![SynGap Research Fund](https://www.rarediseasediversity.org/hs-fs/hubfs/SynGap-Research-Fund.png?width=150&height=80&name=SynGap-Research-Fund.png) ](https://www.syngapresearchfund.org) [![the waiting room entertainment](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/the-waiting-room-entertainment.png?width=150&height=80&name=the-waiting-room-entertainment.png) ](https://www.linkedin.com/in/thewaitingroomentertainment) [![Think Genetic Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/Think-Genetic-Foundation.png?width=150&height=80&name=Think-Genetic-Foundation.png) ](https://thinkgenetic.org) [![Travere Therapeutics](https://www.rarediseasediversity.org/hs-fs/hubfs/Travere-Therapeutics.png?width=150&height=80&name=Travere-Therapeutics.png) ](https://travere.com) [![TSC Alliance](https://www.rarediseasediversity.org/hs-fs/hubfs/TSC-Alliance.png?width=150&height=80&name=TSC-Alliance.png) ](https://www.tscalliance.org) [![A Twist of Fate](https://www.rarediseasediversity.org/hs-fs/hubfs/A-Twist-of-Fate.png?width=150&height=80&name=A-Twist-of-Fate.png) ](http://www.atwistoffate-ats.org) [![UCB](https://www.rarediseasediversity.org/hs-fs/hubfs/UCB.png?width=150&height=80&name=UCB.png) ](https://www.ucb.com) [![UDNF (Undiagnosed Diseases Network Foundation)](https://www.rarediseasediversity.org/hs-fs/hubfs/UDNF.png?width=150&height=80&name=UDNF.png) ](https://commonfund.nih.gov/diseases) [![The Vasculitis Foundation](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/Vasculitis-Foundation.png?width=150&height=80&name=Vasculitis-Foundation.png) ](https://vasculitisfoundation.org) [![VHL Alliance](https://www.rarediseasediversity.org/hs-fs/hubfs/VHL-Alliance.png?width=150&height=80&name=VHL-Alliance.png) ](https://www.vhl.org) [![Vertex](https://www.rarediseasediversity.org/hs-fs/hubfs/Vertex.png?width=150&height=80&name=Vertex.png) ](https://www.vrtx.com) [![Watts Group LLC](https://www.rarediseasediversity.org/hs-fs/hubfs/Watts-Group-LLC.png?width=150&height=80&name=Watts-Group-LLC.png) ](https://www.wattsgroupllc.com) [![ZS logo: Click to visit their web site](https://www.rarediseasediversity.org/hs-fs/hubfs/RDDC/ZS.png?width=150&height=80&name=ZS.png) ](https://www.zs.com) [View All RDDC Partners](https://www.rarediseasediversity.org/rddc-partners?hsLang=en) #### Sign Up for the Latest Updates [![RDDC logo TM](https://www.rarediseasediversity.org/hubfs/RDDC-logo-TM.svg) ](https://www.rarediseasediversity.org?hsLang=en) - [About the Coalition](https://www.rarediseasediversity.org/about) - [What We Do](https://www.rarediseasediversity.org/what-we-do) - [Get Involved](https://www.rarediseasediversity.org/rddc-get-involved) - [Patient Support](https://www.rarediseasediversity.org/additional-patient-support) - [The Latest](https://www.rarediseasediversity.org/the-latest) - [Events](https://www.rarediseasediversity.org/rddc-events) - [* * ](https://www.youtube.com/@RareDiseaseDiversityCoalition) - [* * ](https://www.linkedin.com/company/rare-disease-diversity-coalition/?trk=organization_guest_main-feed-card-text) - [* * ](https://www.instagram.com/rarediseasediversitycoalition) - [* * ](https://www.facebook.com/people/Rare-Disease-Diversity-Coalition/100086789036888) ©2026 Rare Disease Diversity Coalition. All rights reserved. | [Privacy Policy](https://www.rarediseasediversity.org/rddc-privacy-policy?hsLang=en) | [Contact Us](https://www.rarediseasediversity.org/contact-us?hsLang=en) | [Site Credits](https://www.faceliftdesigns.com/)